Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

ESMO Open. 2022 Feb;7(1):100393. doi: 10.1016/j.esmoop.2022.100393. Epub 2022 Feb 4.

¹ UC Davis Comprehensive Cancer Center, Sacramento, USA; University of California, San Francisco School of Pharmacy, San Francisco, USA. Electronic address: [email protected].
² University of California, San Francisco School of Pharmacy, San Francisco, USA.
³ Department of Pharmacy, Oregon Health and Science University, Portland, USA.
⁴ UC Davis Comprehensive Cancer Center, Sacramento, USA; Division of Hematology and Oncology, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, USA.

No abstract available

Publication types